Navigation Links
China Biologic Products Begins Operation of its Newly Constructed Plasma Collection Station in Qi He County, Shandong Province
Date:7/9/2008

iseases.

Safe Harbor Statement

This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the effect of the Qi He Station on the Company's plasma supply; the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For more information, please contact:

Company Contact:

Mr. Y. Tristan Kuo

CFO

China Biologic Products, Inc.

Tel: +86-538-6202206

Email: '/>"/>

SOURCE China Biologic Products, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Colo. and THOUSAND OAKS, Calif., Dec. 14 /PRNewswire-FirstCall/ ... and Amgen Inc.(Nasdaq: AMGN ) today announced ... exclusive worldwide rights to Array,s small-molecule glucokinase activator ... Phase 1 clinical trial in patients with Type ... of the agreement, Array will receive an upfront ...
(Date:12/14/2009)... N.J., Dec. 14 The third edition ... , published by the Infusion ... treatment for anthracycline extravasation.(1) Anthracyclines are a ... and epirubicin that have been used in the ... early 1970s.(2) ,, According to the ...
(Date:12/14/2009)... Dec. 14 Decision Resources, one of ... pharmaceutical and healthcare issues, finds that, owing to ... fibrillation drug market will increase more than sevenfold ... in 2018 in the United States, France, Germany, ... The new Pharmacor report entitled Atrial Fibrillation ...
(Date:12/11/2009)... SEATTLE, Dec. 11 Dendreon Corporation (Nasdaq: ... of its previously announced public offering have exercised ... 2,250,000 shares of common stock at the public ... exercise of the option increases the size of ... of common stock. Dendreon expects to receive ...
Breaking Biology Technology:Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3
... RiverVest Venture Partners,announced today that it has completed ... L.P., with total committed capital of $75,million from ... a Small Business Investment Company, had total private ... from the Small Business Administration., RiverVest co-founder ...
... Jersey, April 11, Rosetta Genomics Ltd. (Nasdaq: ROSG ... and therapeutics, announced,today it will present multiple posters ... The posters will include data on Rosetta Genomics,unique ... to develop,objective and standardized diagnostic tests and therapeutics ...
... 11, 2008 In the event of an outbreak ... changes responsible for virulence or drug resistance is essential ... and analysis of a pathogen genome is time-intensive and ... now developed a comparative genomics strategy to drastically reduce ...
Other Biology Technology:RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner 2RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner 3Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 2Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 3Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 4Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 5Scientists develop strategy to rapidly describe outbreak strains with next-generation DNA sequencing 2
(Date:12/14/2009)... -- MODA Technology Partners, a global software company ... testing for the Pharmaceutical industry, today announced the ... generation mobile data acquisition platform. The latest release ... their regulated manufacturing processes. ,, MODA 3.0 ... Fully-Configurable Test Methods: Each test method in ...
(Date:12/13/2009)... have resolved a question about how a popular ... using biosensors that reveal previously hidden components of ... delusions and hallucinations characterize the illness, people with ... information in a particular order, difficulties that interfere ... function well, said Lee Schroeder, a student in ...
(Date:12/13/2009)... 2009Researchers at The Scripps Research Institute have solved ... from an ancient family of enzymes can have ... addition to providing guidance for understanding other molecules ... underpinning for the protein,s possible use for combating ... research was published in the December 13, 2009 ...
Breaking Biology News(10 mins):MODA Announces Availability of Third Generation Mobile Data Acquisition Platform 2New biosensors reveal workings of anti-psychotic drugs in the living brain 2Scripps Research scientists crack mystery of protein's dual function 2Scripps Research scientists crack mystery of protein's dual function 3Access Pharmaceuticals to Present at the Rodman 26 Renshaw Annual Healthcare Conference 13766 1Access Pharmaceuticals to Present at the Rodman 26 Renshaw Annual Healthcare Conference 13766 2Access Pharmaceuticals to Present at the Rodman 26 Renshaw Annual Healthcare Conference 13766 3LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 1LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 2LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 3LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 4LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 5Thoratec Presentation at Baird Conference to be Webcast 13764 1
... is the shape of the cochlea the snail-shell-shaped organ ... impulses that the brain deciphers which proves to be ... the Proceedings of the National Academy of Sciences establishes a ... limit of more than a dozen different mammals. , The ...
... of patients around the world following a routine dosage ... a frantic search to uncover what could make the ... Institute was among a small group of scientists with ... the source of the contamination. , Robert J. ...
... May Enable Food-Borne Pathogens on Leafy Vegetables ... sequester harmful food-borne pathogens ultimately contributing to their ... Technological University, Cookeville and the Produce Safety and ... their findings in the April 2008 issue of ...
Other Biology News:Study links low-frequency hearing to shape of the cochlea 2Study links low-frequency hearing to shape of the cochlea 3Study links low-frequency hearing to shape of the cochlea 4Deadly dose: Rensselaer heparin expert helps uncover source of lethal contamination 2Tips from the Journals of the American Society for Microbiology 2Tips from the Journals of the American Society for Microbiology 3Tips from the Journals of the American Society for Microbiology 4
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... automates the denaturation and hybridization steps in ... for clinical and research personnel. The low ... sample types, is easy to use, and ... while ensuring overall precision and accuracy in ...
Extremely high efficiency packaging extracts useful for transfecting our EpiFOS™ or CopyControl™ Fosmids, or any DNA vector with cos sites. A tremendous value when conpared to the competition...
... Iodide (PI) is a fluorescent nucleic acid ... acids. As a nuclear counterstain, propidium ... red in color. The fluorescent red ... blue fluorochromes such as FITC, Cy2 or ...
Biology Products: